Wendy Waegell Phones & Addresses
-
7 Rice Corner Rd, Brookfield, MA 01506 (508) 867-9642
-
Chicago, IL
-
1 Selden St, Worcester, MA 01605 (508) 853-9205 (508) 854-0539
-
28 Ridgeland Rd, Shrewsbury, MA 01545 (508) 799-9716
-
Newark, CA
-
Redwood City, CA
-
Palo Alto, CA
Publications
Us Patents
Monoclonal Antibodies To Transforming Growth Factor-Beta And Methods Of Use
View pageUS Patent:
6419928, Jul 16, 2002
Filed:
Mar 21, 2000
Appl. No.:
09/531383
Inventors:
James R. Dasch - Palo Alto CA
Wendy O. Waegell - Mountain View CA
Wendy O. Waegell - Mountain View CA
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
A61K 39395
US Classification:
4241581, 4241331, 4241411, 4241721, 4241521, 5303881, 5303873, 53038873
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Monoclonal Antibodies To Tgf-Beta
View pageUS Patent:
20020176858, Nov 28, 2002
Filed:
Jun 17, 2002
Appl. No.:
10/173074
Inventors:
James Dasch - Needham MA, US
Doran Pace - San Francisco CA, US
Wendy Waegell - Worcester MA, US
Doran Pace - San Francisco CA, US
Wendy Waegell - Worcester MA, US
International Classification:
A61K039/395
C12N005/06
C07K016/22
C12N005/06
C07K016/22
US Classification:
424/145100, 530/388240, 435/336000
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Method Of Treating Transplant Rejection
View pageUS Patent:
20050008640, Jan 13, 2005
Filed:
Apr 23, 2004
Appl. No.:
10/831763
Inventors:
Wendy Waegell - Brookfield MA, US
Gavin Hirst - Princeton MA, US
Gavin Hirst - Princeton MA, US
International Classification:
A61K038/40
A61K038/13
A61K031/541
A61K031/5377
A61K031/519
A61K039/395
A61K038/13
A61K031/541
A61K031/5377
A61K031/519
A61K039/395
US Classification:
424145100, 514265100, 514227800, 514234200, 514252160, 514291000, 514011000, 514449000, 514109000, 514006000, 514171000
Abstract:
This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.
Immunobinders Directed Against Sclerostin
View pageUS Patent:
20130171096, Jul 4, 2013
Filed:
Oct 24, 2012
Appl. No.:
13/659647
Inventors:
Chung-Ming Hsieh - Newton MA, US
Alexander Ivanov - Lexington MA, US
Wendy Waegell - Brookfield MA, US
Alexander Ivanov - Lexington MA, US
Wendy Waegell - Brookfield MA, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
C07K 16/18
A61K 31/56
A61K 31/353
A61K 38/17
A61K 38/21
A61K 38/20
A61K 31/519
A61K 31/439
A61K 38/13
A61K 38/18
A61K 31/4439
A61K 38/19
A61K 39/395
A61K 31/44
A61K 31/56
A61K 31/353
A61K 38/17
A61K 38/21
A61K 38/20
A61K 31/519
A61K 31/439
A61K 38/13
A61K 38/18
A61K 31/4439
A61K 38/19
A61K 39/395
A61K 31/44
US Classification:
424 852, 5303892, 536 2353, 4353201, 435 696, 4241581, 5303873, 5303917, 5303913, 435335, 435419, 43525421, 43525233, 424 855, 424 851
Abstract:
Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
Monoclonal Antibodies Which Bind Both Transforming Growth Factors .Beta.1 And .Beta.2 And Methods Of Use
View pageUS Patent:
55717144, Nov 5, 1996
Filed:
Sep 6, 1991
Appl. No.:
7/759109
Inventors:
James R. Dasch - Palo Alto CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Assignee:
Celtrix Pharmaceuticals, Inc. - Santa Clara CA
International Classification:
C12N 520
C07K 1622
C12P 2108
A61K 39395
C07K 1622
C12P 2108
A61K 39395
US Classification:
43524027
Abstract:
Monoclonal antibodies have been produced which bind to Transforming Growth Factors. beta. 1 (TGF-. beta. 1) and. beta. 2 (TGF-. beta. 2). The monoclonal antibody produced by the hybridoma designated 1D11. 16 deposited as A. T. C. C. Accession No. HB 9849 binds to both TGF-. beta. 1 and TGF-. beta. 2. The antibodies are produced by immunizing with TGF-. beta. 2 and may be of any isotype. The antibodies may be of any mammalian origin such as murine or human origin. Diagnostic and therapeutic applications utilizing the monoclonal antibodies are also disclosed.
Monoclonal Antibodies To Transforming Growth Factor-.Beta. And Methods Of Use
View pageUS Patent:
6090383, Jul 18, 2000
Filed:
Jun 15, 1998
Appl. No.:
9/097843
Inventors:
James R. Dasch - Palo Alto CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
International Classification:
A61K 3940
A61K 39395
G01N 33574
C12P 2108
C07K 1600
A61K 39395
G01N 33574
C12P 2108
C07K 1600
US Classification:
4241331
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Monoclonal Antibodies To Transforming Growth Factor-Beta And Methods Of Use
View pageUS Patent:
57831858, Jul 21, 1998
Filed:
May 4, 1995
Appl. No.:
8/434977
Inventors:
James R. Dasch - Palo Alto CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Assignee:
Celtrix Pharmaceuticals, Inc. - Santa Clara CA
International Classification:
A61K 39395
C07K 1622
C07K 1622
US Classification:
4241331
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications for treating or reducing the likelihood of developing acute or chronic fibrosis utilizing the TGF-B monoclonal antibody are also disclosed.
Monoclonal Antibodies To Transforming Growth Factor-Beta And Methods Of Use
View pageUS Patent:
57729980, Jun 30, 1998
Filed:
May 4, 1995
Appl. No.:
8/434976
Inventors:
James R. Dasch - Palo Alto CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Doran R. Pace - San Francisco CA
Wendy O. Waegell - Mountain View CA
Assignee:
Celtrix Pharmaceuticals, Inc. - Santa Clara CA
International Classification:
A61K 39395
C07K 1622
C07K 1622
US Classification:
4241331
Abstract:
Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.